Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 4:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: IV Placebo 100 mL solution Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of the Efficacy and Safety of Intravenous vs Oral Acetaminophen for Treatment of Fever in Healthy Adult Males

NCT00564629
View directory record Official record
Conditions
Fever
Interventions
Intravenous acetaminophen plus oral placebo, Oral acetaminophen plus IV placebo, Reference standard endotoxin (RSE)
Drug · Biological
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years to 75 Years · Male only
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 18, 2016 · Synced Sep 23, 2026, 4:30 AM EDT
Completed Phase 2 Interventional

A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor

NCT01851070
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Allogeneic Mesenchymal Precursor Cells, Normal Saline
Drug
Lead sponsor
Mesoblast, Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
20
States / cities
Anniston, Alabama • Gilbert, Arizona • El Cajon, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2020 · Synced Sep 23, 2026, 4:30 AM EDT
Active, not recruiting Phase 2 Interventional

Efficacy of Amicar for Children Having Craniofacial Surgery

NCT02229968
View directory record Official record
Conditions
Craniosynostosis
Interventions
Amicar (ε-aminocaproic acid), normal saline
Drug
Lead sponsor
Children's National Research Institute
Other
Eligibility
2 Months to 36 Months
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Sep 23, 2026, 4:30 AM EDT
Completed Phase 4 Interventional Results available

RCT (Randomized Controlled Trial) of IV Acetaminophen for Post Cesarean Pain Relief

NCT02046382
View directory record Official record
Conditions
Cesarean Section, Pain, Postoperative
Interventions
IV Acetaminophen, Placebo
Drug
Lead sponsor
TriHealth Inc.
Other
Eligibility
18 Years and older · Female only
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 15, 2018 · Synced Sep 23, 2026, 4:30 AM EDT
Terminated Phase 2 Interventional Results available

High Dose Intravenous Ascorbic Acid in Severe Sepsis

NCT02734147
View directory record Official record
Conditions
Sepsis
Interventions
Ascorbic Acid, Normal Saline
Drug · Other
Lead sponsor
Christiana Care Health Services
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Feb 15, 2021 · Synced Sep 23, 2026, 4:30 AM EDT
Completed Phase 2 Interventional Results available

Crizanlizumab for Treating COVID-19 Vasculopathy

NCT04435184
View directory record Official record
Conditions
COVID-19
Interventions
Crizanlizumab, 0.9% saline
Drug · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Sep 23, 2026, 4:30 AM EDT
Completed Phase 1Phase 2 Interventional

Zofin to Treat COVID-19 Long Haulers

NCT05228899
View directory record Official record
Conditions
COVID-19
Interventions
Zofin, Placebo
Drug · Other
Lead sponsor
ZEO ScientifiX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
4
States / cities
Newport Beach, California • North Hollywood, California • Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2023 · Synced Sep 23, 2026, 4:30 AM EDT
Recruiting Phase 3 Interventional

A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)

NCT06439082
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Crizanlizumab, Placebo
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 100 Years
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
17
States / cities
Birmingham, Alabama • Orange, California • Washington D.C., District of Columbia + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 23, 2026, 4:30 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Effect and Safety of AZD6765 in Patients With Major Depressive Disorder

NCT01482221
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
AZD6765 iv, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
542 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
33
States / cities
Chino, California • Lond Beach, California • San Diego, California + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Sep 23, 2026, 4:30 AM EDT
Terminated Phase 3 Interventional Results available

Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)

NCT02626455
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin
Interventions
Copanlisib (BAY80-6946), Placebo, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Bendamustine, Prednisone
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
551 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
10
States / cities
Chandler, Arizona • West Covina, California • Denver, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Sep 23, 2026, 4:30 AM EDT
Terminated Phase 2 Interventional Results available

Efprezimod Alfa (CD24Fc, MK-7110) Administration to Decrease Low-Density Lipoprotein (LDL) and Inflammation in Human Immunodeficiency Virus (HIV) Patients (CALIBER) (MK-7110-003)

NCT03960541
View directory record Official record
Conditions
HIV Infections, Dyslipidemias
Interventions
Efprezimod alfa (human CD24 extracellular domain and human IgG1 Fc fusion protein), Saline Solution
Drug
Lead sponsor
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
50 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 7, 2023 · Synced Sep 23, 2026, 4:30 AM EDT
Completed Not applicable Interventional Results available

Intraoperative and Post-operative Analgesic Effect of IV Acetaminophen for Sinus Surgery

NCT01608308
View directory record Official record
Conditions
Chronic Sinusitis
Interventions
IV Acetaminophen, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 68 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2015 · Synced Sep 23, 2026, 4:30 AM EDT
Recruiting Phase 1Phase 2 Interventional

Stem Cells for Erectile Dysfunction Post RALP

NCT07048314
View directory record Official record
Conditions
Erectile Dysfunction, Prostate Cancer
Interventions
Allogeneic adipose-derived mesenchymal stem cells (HB-adMSCs) at the doctor's office, Allogeneic adipose-derived mesenchymal stem cells (HB-adMSCs) in the OR, Placebo in the OR, Placebo in clinic
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
40 Years to 70 Years · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 23, 2026, 4:30 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Eptinezumab for the Prevention of Migraine in Participants That Are Not Helped by Previous Preventive Treatments

NCT04418765
View directory record Official record
Conditions
Migraine
Interventions
Eptinezumab, Placebo
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
892 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
14
States / cities
Walnut Creek, California • Gainesville, Florida • Maitland, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Sep 23, 2026, 4:30 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients

NCT03814746
View directory record Official record
Conditions
Sickle Cell Disease (SCD)
Interventions
Crizanlizumab (SEG101), Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 100 Years
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
5
States / cities
Atlanta, Georgia • Boston, Massachusetts • Charlotte, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2026 · Synced Sep 23, 2026, 4:30 AM EDT
Completed Phase 3 Interventional Results available

Safety and Tolerability of Intravenous Brivaracetam (Infusion or Bolus) as Adjunctive Antiepileptic Therapy

NCT01405508
View directory record Official record
Conditions
Epilepsy
Interventions
Brivaracetam tablets, Brivaracetam bolus, Brivaracetam infusion, Placebo
Drug · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
16 Years to 70 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
8
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Lexington, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Sep 23, 2026, 4:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

To Assess the Safety, Tolerability and Pharmacokinetics of AZD5634 Following Inhaled and Intravenous (IV)Dose Administration

NCT02679729
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
AZD5634 for inhalation, AZD5634 for infusion, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 50 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
2
States / cities
Glendale, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 4, 2018 · Synced Sep 23, 2026, 4:30 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Improving Pain Control in Paraesophageal Hernia Repair: Intravenous Lidocaine Versus Placebo

NCT04096170
View directory record Official record
Conditions
Hernia, Paraesophageal
Interventions
IV lidocaine, Placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 23, 2026, 4:30 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Intravenous Acetaminophen Over 48 Hrs for the Treatment of Post-op Pain After Gynecologic Surgery

NCT00399568
View directory record Official record
Conditions
Postoperative Pain, Hysterectomy
Interventions
IV Acetaminophen, IV Placebo 100 mL solution
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
27
States / cities
Birmingham, Alabama • Sheffield, Alabama • Phoenix, Arizona + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2016 · Synced Sep 23, 2026, 4:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Escalating Doses of GSK1325756 Solution for Infusion, and Absolute Bioavailability Relative of an Oral Dose, in Healthy Adult Subjects

NCT02169583
View directory record Official record
Conditions
Infections, Respiratory Tract
Interventions
GSK1325756 Solution, GSK1325756 Solution Matching Placebo, GSK1325756 Tablet, GSK1325756 Tablet Matching Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 14, 2017 · Synced Sep 23, 2026, 4:30 AM EDT
Terminated Phase 2 Interventional Results available

GSK2251052 in Complicated Urinary Tract Infection

NCT01381549
View directory record Official record
Conditions
Infections, Urinary Tract
Interventions
GSK2251052, imipenem-cilastatin, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
4
States / cities
Los Angeles, California • Council Bluffs, Iowa • Topeka, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2017 · Synced Sep 23, 2026, 4:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Drug Levels of an Antibody Against HIV in Healthy, HIV-Uninfected Adults

NCT02165267
View directory record Official record
Conditions
HIV Infections
Interventions
VRC01, SC placebo for VRC01, IV placebo for VRC01
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
6
States / cities
Boston, Massachusetts • New York, New York • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Sep 23, 2026, 4:30 AM EDT
Completed Phase 2Phase 3 Interventional

Impact of Intravenous Iron Repletion On Mechanisms of Exercise InTolerance in HFpEF (IRONMET-HFpEF)

NCT04945707
View directory record Official record
Conditions
Iron-deficiency, Heart Failure With Preserved Ejection Fraction
Interventions
Ferric Derisomaltose 1000 Mg in 100 mL INTRAVENOUS SOLUTION [Monoferric], Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 23, 2026, 4:30 AM EDT
Completed Phase 2 Interventional Results available

Phase II Trial of Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft-Versus-Host Disease (GVHD) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-002)

NCT02663622
View directory record Official record
Conditions
Graft Versus Host Disease, Hematopoietic Stem Cell Transplantation, Leukemia
Interventions
Efprezimod alfa, Methotrexate, Tacrolimus, Placebo
Drug
Lead sponsor
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
4
States / cities
Indianapolis, Indiana • Ann Arbor, Michigan • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2024 · Synced Sep 23, 2026, 4:30 AM EDT